Combivir Articles
FDA denies Citizen Petition on generic Combivir 180-day exclusivity “First Applicant” issue
3 June 2011
Mylan confirms first-to-file patent challenge to Cephalon’s sleep-disorder drug Nuvigil
12 January 2010
FDA panel OKs Pfizer’s Selzentry for broader us in HIV naive patients, but drug criticized for its cost
12 October 2009
Less side effects with switch from Combivir to Truvada
5 November 2007
Truvada/Sustiva cuts viral load vs Combivir/Sustiva
6 August 2007
GlaxoSmithKline in deal to supply HIV/AIDS drugs to Russia
25 September 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
Mixed data from S-P's vicriviroc in HIV study
20 February 2006
Good efficacy for Gilead Sci's ARV combo
30 January 2006
GSK says combination HIV therapy increases treatment adherence
12 December 2005
WHO, US FDA to share generic HIV/AIDS Rx data
22 August 2005
Aurobindo gets tentative appro for generic ARV
18 July 2005
More US FDA HIV/AIDS drug approvals "soon"
14 March 2005
GSK rebrands HIV/ AIDS drugs for Africa
28 February 2005
Gilead reports 48-wk data from HIV study
14 February 2005
US FDA OKs first ARV triple therapy for LDCs
31 January 2005
BI and GSK to co-package HIV drugs
19 July 2004
BI and GSK to co-package HIV drugs
19 July 2004
GSK ARVs placed on EU anti-diversion list
3 May 2004
GSK urges Nigeria to use ARV duty waiver
19 April 2004
GSK moves to stop AIDS drug smugglers
5 January 2004
US/S African on-line pharmacy offering cheap HIV/AIDS drugs
8 September 2003
Gilead starts Viread/Emtriva combi study
18 August 2003
GSK cuts HIV/AIDS Rx prices to LDCs again
5 May 2003
Activists fire shot at GSK over Trizivir study
17 March 2003
New ARVs
10 February 2003
AIDS group demonstrates against GSK
22 July 2002
Kenyan HIV/AIDS drug shortages hit patients
29 April 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
HIV/AIDS patients "must get drug treatment," says Mandela
3 December 2001
Immune Response cancels Remune trial
3 September 2001
Superior efficacy for Ziagen/Combivir
11 July 2001
BI's tipranavir effective as HIV salvage regimen
10 July 2001
Burundi signs up for UN HIV/AIDS drug plan
2 May 2001
Mali, Cameroon to get cheap HIV/AIDS drugs
11 April 2001
GSK: "Combivir's price goes no lower"
9 April 2001
GSK "surprise" at SA HIV/AIDS drugs claim
23 February 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
Cipla talks with MNCs over HIV drug offer
13 February 2001
Earnings increase 41% at BioChem Pharma
1 February 2001
S Africa OKs generic Diflucan imports
1 December 2000
GW wins FDA approval for Trizivir
16 November 2000
HIV/AIDS therapy sales forecasts to 2009
3 August 2000
BioChem Pharma earnings up 34%
3 May 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
BioChem Pharma profits up 17%
29 October 1999
Sustiva, Combivir "beat HIV non-compliance"
13 October 1999
Remune combo trial
27 September 1999
Sharp earnings rise at BioChem Pharma
2 August 1999
GW gains EU approval for Ziagen
13 July 1999
BioChem Pharma posts 39% revenue rise
5 May 1999
South Africa tells AIDS drugmakers:cut your prices
30 April 1999
US HIV conference data in brief
4 February 1999
Epivir boosts earnings at BioChem Pharma
3 February 1999
Low compliance could fuel AIDS epidemic
26 January 1999
G-W's Ziagen approved in USA
21 December 1998
Canada Approve Combivir for HIV Infection
9 December 1998
GW's Ziagen Endorsed By FDA Committee
3 November 1998
First Approval Of DuPont's Sustiva In USA
21 September 1998
Review Of US Second Qtr & Implications For Euro Firms
20 August 1998
Healthy 2nd Qtr Sales/ Earnings At BioChem
5 August 1998
GW's Abacavir Combo As Potent As PI Regimen
30 June 1998
GW's Combivir OKed In EU
19 March 1998
Glaxo Wellcome Profits Hit By Strength Of Sterling
19 February 1998
B-MS' Zerit Overtakes Glaxo's Zidovudine
30 January 1998
EU Approval Granted For Combivir
4 December 1997
UK Approves GW's Combivir
27 November 1997
GW's Combivir Approved In The USA For HIV
1 October 1997
Showing 1-86 of 86 articles
- 1
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
